Arcadis N.V.
13.1.2021 07:01:28 CET | Globenewswire | Press release
13 January 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 79,198 of its own shares in the period from 6 January 2021 up to and including 12 January 2021 at an average price of €29.98. The consideration of this repurchase was €2.4 million. The repurchase is in accordance with the share buyback program to cover obligations from employee incentive plans, as announced on 30 December 2020.
The total number of shares repurchased under this program to date is 133,909 shares for a total consideration of €3.9 million.
For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/
-End -
FOR FURTHER INFORMATION PLEASE CONTACT:
ARCADIS INVESTOR RELATIONS
Jurgen Pullens
Mobile: +31 6 51599483
E-mail: jurgen.pullens@arcadis.com
ABOUT ARCADIS
Arcadis is a leading global Design & Consultancy organization for natural and built assets. Applying our deep market sector insights and collective design, consultancy, engineering, project and management services we work in partnership with our clients to deliver exceptional and sustainable outcomes throughout the lifecycle of their natural and built assets. We are 28,000 people, active in over 70 countries that generate €3.5 billion in revenues. We support UN-Habitat with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. www.arcadis.com
.
REGULATED INFORMATION
This press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation
Attachments
- Arcadis reports transactions under its current share buyback program week 2
- 2021 Arcadis Share Buyback program
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Zymeworks Inc.15.6.2026 00:05:00 CEST | Press release
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Crinetics Pharmaceuticals, Inc.14.6.2026 22:30:00 CEST | Press release
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
Crinetics Pharmaceuticals, Inc.14.6.2026 20:45:00 CEST | Press release
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
King Faisal Specialist Hospital & Research Centre14.6.2026 09:01:00 CEST | Press release
KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026
Genmab A/S13.6.2026 18:45:00 CEST | Press release
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
